We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$290M
1-Year Est. Return
143.88%
This Fund
S&P 500
This Quarter
Est. Return
-12.02%
1 Year Est. Return
+143.88%
3 Year Est. Return
+150.93%
5 Year Est. Return
+74.33%
10 Year Est. Return
–
AUM
$309M
AUM Growth
-$44.4M
(-13%)
Cap. Flow
+$9.41M
Cap. Flow
% of AUM
3.04%
Top 10 Holdings %
Top 10 Hldgs %
81.18%
Holding
24
New
2
Increased
3
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fulcrum Therapeutics
FULC
|
+$18.7M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$18.3M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$9.12M |
| 4 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$7.78M |
| 5 |
Voyager Therapeutics
VYGR
|
+$6.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Replimune Group
REPL
|
+$18M |
| 2 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$6.9M |
| 3 |
Veracyte
VCYT
|
+$5.7M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$5.04M |
| 5 |
Alector
ALEC
|
+$3.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.75% |
| 2 | Miscellaneous | 1.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $68.7M | 22.19% |
1,826,374
-3,891
| -0.2% | -$169K |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $26.9M | 8.7% |
1,400,900
+800,900
| +133% | +$18.3M |
|
3
Insmed
INSM
$26.2B
| $25.2M | 8.15% |
1,429,518
-131,667
| -8% | -$2.54M |
|
|
MDCO
4
DELISTED
Medicines Co
MDCO
| $23.9M | 7.73% |
478,217
+228,545
| +92% | +$9.12M |
|
5
Ascendis Pharma A/S
ASND
$15.8B
| $23.6M | 7.64% |
245,424
| – | – |
|
6
Cytokinetics
CYTK
$9.64B
| $21.6M | 6.98% |
1,898,970
| – | – |
|
|
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $17.8M | 5.74% |
425,794
-3,896
| -0.9% | -$165K |
|
|
OPTN
8
DELISTED
OptiNose
OPTN
| $15.7M | 5.06% |
149,200
-18,946
| -11% | -$1.89M |
|
|
9
Voyager Therapeutics
VYGR
$190M
| $14.3M | 4.62% |
830,565
+293,794
| +55% | +$6.17M |
|
|
10
Alector
ALEC
$227M
| $13.5M | 4.36% |
936,371
-207,091
| -18% | -$3.74M |
|
|
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $12.4M | 4.01% |
238,186
-19,266
| -7% | -$1.02M |
|
|
12
Fulcrum Therapeutics
FULC
$288M
| $11.2M | 3.62% |
+1,687,500
| New | +$18.7M |
|
|
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
| $10.5M | 3.41% |
2,060,268
-510,990
| -20% | -$3.09M |
|
|
ORTX
14
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $6.63M | 2.14% |
+55,770
| New | +$7.78M |
|
|
15
Rhythm Pharmaceuticals
RYTM
$6.66B
| $5.06M | 1.64% |
234,482
-235,000
| -50% | -$5.04M |
|
|
IMMU
16
DELISTED
Immunomedics Inc
IMMU
| $4.88M | 1.58% |
367,636
-18,115
| -5% | -$266K |
|
17
SI-BONE Inc
SIBN
$831M
| $3.63M | 1.17% |
205,621
| – | – |
|
|
AERI
18
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| $1.93M | 0.62% |
100,500
| – | – |
|
|
AERI
19
PUT
DELISTED
Aerie Pharmaceuticals
AERI
| $1.93M | 0.62% |
100,500
| – | – |
|
20
Arbutus Biopharma
ABUS
$1B
| – | – |
-608,151
| Closed | -$1.26M |
|
21
Kiniksa Pharmaceuticals
KNSA
$5.86B
| – | – |
-63,922
| Closed | -$866K |
|
|
22
Replimune Group
REPL
$1.23B
| – | – |
-1,228,656
| Closed | -$18M |
|
|
23
Veracyte
VCYT
$3.23B
| – | – |
-200,000
| Closed | -$5.7M |
|
|
NGM
24
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| – | – |
-471,269
| Closed | -$6.9M |
|
Similar funds
NWP
BCP
NC
KLCMU
SIA
MPWS
RC
VG
Foresite Capital Management IV's Q3 2019 Portfolio in Review
As of Q3 2019, Foresite Capital Management IV held 24 positions worth $309M, down 13% from $354M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Foresite Capital Management IV deployed $9.41M of net new capital in Q3 2019, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Fulcrum Therapeutics: 1,687,500 shares worth $11.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Rhythm Pharmaceuticals, an estimated $5.04M trimmed.
- Foresite Capital Management IV's largest Q3 2019 buy was Fulcrum Therapeutics: 1,687,500 shares worth $11.2M.
- Foresite Capital Management IV added most to Aerie Pharmaceuticals in Q3 2019, an estimated $18.3M increase.
- Foresite Capital Management IV's biggest Q3 2019 reduction was Rhythm Pharmaceuticals, cutting an estimated $5.04M.
- Foresite Capital Management IV fully exited Replimune Group in Q3 2019, selling an estimated $18M.
- Foresite Capital Management IV's ten largest holdings make up 81% of its $309M portfolio in Q3 2019.
- Foresite Capital Management IV opened 2 new positions and closed 5 in Q3 2019.
- Foresite Capital Management IV's portfolio value fell 13% quarter-over-quarter to $309M.
Based on Foresite Capital Management IV's 13F filing for Q3 2019, filed 13 Nov 2019.